International Scholarly Research Notices

International Scholarly Research Notices / 2013 / Article

Research Article | Open Access

Volume 2013 |Article ID 428378 |

Talambedu Usha, Pranav Tripathi, Veena Pande, Sushil Kumar Middha, "Molecular Docking and Quantum Mechanical Studies on Pelargonidin-3-Glucoside as Renoprotective ACE Inhibitor", International Scholarly Research Notices, vol. 2013, Article ID 428378, 4 pages, 2013.

Molecular Docking and Quantum Mechanical Studies on Pelargonidin-3-Glucoside as Renoprotective ACE Inhibitor

Academic Editor: B. Oliva
Received21 Jan 2013
Accepted24 Feb 2013
Published28 Mar 2013


Background and Aim. Despite tangible progress in recent years, substantial therapeutic challenges remain unexplored in nephropathy, particularly in diabetic patient. Addressing these challenges requires identification of novel drugs and development of noninvasive and cost-effective methods to select the most appropriate therapeutic option for the disease. Angiopathic nephropathy is one of the complications of diabetes mellitus and is becoming the single most important reason for end-stage renal disease in the western world. This study has investigated the inhibitory effect of a library naturally occurring nonprotein compounds that inhibit angiotensin converting enzyme (ACE). Materials and Methods. Docking studies of ACE protein with natural compounds and synthetic commercial drug perindopril were done using AutoDock, FlexX, and Hex. Toxicity predictions were carried out using OpenTox. Quantum mechanical properties were studied using GAMESS. Results. Pelargonidin-3-glucoside could be used as a potent renoprotective drug candidate, which inhibits ACEII. It has low toxicity and its quantum mechanical properties are comparable to those of commercial drugs.

1. Introduction

Angiotensin converting enzyme (ACE) is an active participant in the body’s renin-angiotensin-aldosterone system for mediation of extracellular volume and arterial vasoconstriction. Secretion of this enzyme is carried by pulmonary and renal endothelial cells to catalyze the conversion of decapeptide angiotensin I to octapeptide angiotensin [1]. Apart from the normal catalysis activity, ACE also degrades bradykinin thus acting as a vasoconstrictor [2]. These two actions make ACE inhibition a potent target in the treatment of conditions such as hypertension, heart failure, and diabetic nephropathy. Inhibition of ACE results in the dwindled formation of angiotensin II and reduced catabolism of bradykinin, leading to systematic dilation of the arteries and veins and a decrease in arterial blood pressure. Inhibition of this enzyme also decreases the risk of end-stage renal disease (ESRD) in diabetics [3]. perindopril is a synthetic chemical drug which inhibits ACE; however, it causes dysfunctioning of the left ventricle of in Duchenne muscular dystrophy [4]. Considering the side effects of perindopril, the present study investigates the inhibitory effect of natural compounds in comparison with perindopril by insilico approach.

2. Materials and Methods

To investigate the protein ligand interaction, the natural compounds and perindopril were docked into the active site of ACE predicted by pocket finder. The crystal structure of ACE was retrieved from the RCSB Protein Data Bank (PDB entry code 2XY9). Structures of all the compounds were constructed and minimized using MarvinSketch [5]. Docking and hydrogen bonding were done using AutoDock Vina [6], Flex-X [7], HEX6.3 [8, 9], and SPDBV [10], respectively, at default parameters. The molecular dynamics was explored using MD Movie part of UCSF Chimera [11]. The ADME values of natural compounds were calculated online using ADME tool of SIMCYP [12]. Toxicity of the lead compound was calculated using OpenTox online tool [13]. To increase the firmness of the observations, the natural compounds and commercial drugs were quantum mechanically examined and positive results are therefore investigated and analyzed using GAMESS [14] and CHEMISSIAN [15].

3. Results

The acute toxicity in fish was estimated to be about 0.53 (F96h-LogLC50 mmol/L) calculated using OpenTox server. The docking results with molecular, ADME properties of the best natural compound, and the perindopril are listed in Table 1. The above scores establish pelargonidin-3-glucoside as a better compound in comparison to commercial drugs like perindopril.

(in gms)


The quantum mechanical properties of the lead compound were examined along with the commercial drug to investigate the energy band diagrams of the molecular orbitals and the electron densities based on density functional Theory. The energy bands reveal a positive correlation between drug and lead compound as the molecular orbitals are depicted in the same energy band (Figure 1).

The electron densities also depict affirmative results to establish similarity between the lead compound and commercial drug as shown in Figure 2.

Assenting prediction of the binding site for the inhibition of the enzyme has also been achieved as depicted in Figure 3.

4. Discussions

Pelargonidin-3-glucoside is a zenith anthocyanin present in of Zea mays [16]. The above mentioned results for renoprotection are the very first of its type in the current scientific arena. On the basis of results of docking score, molecular dynamics, hydrogen bonding pattern, and ADME-T values, we can conclude that natural compound pelargonidin-3-glucoside from Zea mays is found to be unsurpassed in comparison with synthetic drugs like perindopril. The ADME properties showed satisfactory results for the , , solubility, molar refractivity, and topological PSA of pelargonidin-3-glucoside. The toxicity minutiae were calculated using OpenTox server. The compound was evaluated to have pKa-SMARTS of 4.79, and regarding biodegradability, class II like persistence was reckoned. Pelargonidin-3-glucoside is also analyzed as a non-carcinogen and non-irritant for eye and skin. Pelargonidin 3-O-β-glucopyranoside is a natural colorant found in strawberries [17], pomegranate fruit [18], peel [19, 20], and flowers [21]. The quantum mechanical properties are inferring a compelling possibility of showing drug-like typescript by analysis of electron densities and energy band diagram of molecular orbitals which are similar to perindopril. Thus this compound can be deliberated as a better compound against hypertension and for decreasing the risk of ESRD.


The authors are thankful to DBT-BIF Center, Maharani Lakshmi Ammanni College for Women and Kumaun University for providing the laboratory and licensed facility.


  1. M. Moser, C. Rosendorff, and W. B. White, “Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: is there a difference in response and any advantage to using them together in the treatment of hypertension?” Journal of Clinical Hypertension, vol. 10, no. 6, pp. 489–496, 2008. View at: Publisher Site | Google Scholar
  2. M. E. Marketou and P. E. Vardas, “Bradykinin in the treatment of arterial hypertension: friend or foe?” Hellenic Journal of Cardiology, vol. 53, pp. 91–94, 2012. View at: Google Scholar
  3. S. Suissa, T. Hutchinson, J. M. Brophy, and A. Kezouh, “ACE-inhibitor use and the long-term risk of renal failure in diabetes,” Kidney International, vol. 69, no. 5, pp. 913–919, 2006. View at: Publisher Site | Google Scholar
  4. D. Duboc, C. Meune, G. Lerebours, J. Y. Devaux, G. Vaksmann, and H. M. Bécane, “Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy,” Journal of the American College of Cardiology, vol. 45, no. 6, pp. 855–857, 2005. View at: Publisher Site | Google Scholar
  5. “Marvin was used for drawing, displaying and characterizing chemical structures, substructures and reactions, Marvin 5.8.0 (324),” 2008, ChemAxon, View at: Google Scholar
  6. O. Trott and A. J. Olson, “Software news and update AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading,” Journal of Computational Chemistry, vol. 31, no. 2, pp. 455–461, 2010. View at: Publisher Site | Google Scholar
  7. M. Rarey, B. Kramer, T. Lengauer, and G. Klebe, “A fast flexible docking method using an incremental construction algorithm,” Journal of Molecular Biology, vol. 261, no. 3, pp. 470–489, 1996. View at: Publisher Site | Google Scholar
  8. D. W. Ritchie and V. Venkatraman, “Ultra-fast FFT protein docking on graphics processors,” Bioinformatics, vol. 26, no. 19, Article ID btq444, pp. 2398–2405, 2010. View at: Publisher Site | Google Scholar
  9. B. Bhattacharjee, T. Usha, S. Sadegh et al., “Computer aided screening of inhibitors to 5-α reductase type 2 for prostate,” Bioinformation, vol. 6, no. 7, pp. 262–265, 2011. View at: Publisher Site | Google Scholar
  10. B. Bhattacharjee, R. M. Jayadeepa, R. Anantharamanan, S. S. Pillay, N. Kumari, and S. K. Middha, “Screening of novel inhibitors for MEK1 induced Breast Cancer-An Insilico Approach,” EMBnet Journal A, vol. 16, pp. 25–26, 2009. View at: Google Scholar
  11. E. F. Pettersen, T. D. Goddard, C. C. Huang et al., “UCSF Chimera-a visualization system for exploratory research and analysis,” Journal of Computational Chemistry, vol. 25, no. 13, pp. 1605–1612, 2004. View at: Publisher Site | Google Scholar
  12. D. B. Turner, A. Rostami-Hodjegan, G. T. Tucker, and K. R. Yeo, “Prediction of non-specific hepatic microsomal binding from radily available physicochemical properties,” Drug Metabolism Reviews, vol. 38, no. 1, p. 162, 2006. View at: Google Scholar
  13. E. L. Willighagen, N. Jeliazkova, B. Hardy, R. C. Grafström, and O. Spjuth, “Computational toxicology using the OpenTox application programming interface and Bioclipse,” BMC Research Notes, vol. 4, p. 487, 2011. View at: Publisher Site | Google Scholar
  14. M. W. Schmidt, K. K. Baldridge, J. A. Boatz et al., “General atomic and molecular electronic structure system,” Journal of Computational Chemistry, vol. 14, no. 11, pp. 1347–1363, 1993. View at: Publisher Site | Google Scholar
  16. Y. S. Moreno, G. S. Sánchez, D. R. Hernández et al., “Characterization of anthocyanin extracts from maize kernels,” Journal of Chromatography Science, vol. 43, no. 9, pp. 483–487, 2005. View at: Google Scholar
  17. C. Felgines, O. Texier, C. Besson, B. Lyan, J. L. Lamaison, and A. Scalbert, “Strawberry pelargonidin glycosides are excreted in urine as intact glycosides and glucuronidated pelargonidin derivatives in rats,” British Journal of Nutrition, vol. 98, no. 6, pp. 1126–1131, 2007. View at: Publisher Site | Google Scholar
  18. Y. Noda, T. Kaneyuki, A. Mori, and L. Packer, “Antioxidant activities of pomegranate fruit extract and its anthocyanidins: delphinidin, cyanidin, and pelargonidin,” Journal of Agricultural and Food Chemistry, vol. 50, no. 1, pp. 166–171, 2002. View at: Publisher Site | Google Scholar
  19. S. K. Middha and T. Usha, “An in vitro new vista to identify hypoglycemic activity,” International Journal of Fundamental and Applied Science, vol. 1, no. 2, pp. 27–29, 2012. View at: Google Scholar
  20. T. Tanaka, G. I. Nonaka, and I. Nishioka, “Tannins and related compounds. C. Reaction of dehydrohexahydroxydiphenic acid esters with bases, and its application to the structure determination of pomegranate tannins, granatins A and B,” Chemical and Pharmaceutical Bulletin, vol. 38, no. 9, pp. 2424–2428, 1990. View at: Google Scholar
  21. L. Zhang, Q. Fu, and Y. Zhang, “Composition of anthocyanins in pomegranate flowers and their antioxidant activity,” Food Chemistry, vol. 127, no. 4, pp. 1444–1449, 2011. View at: Publisher Site | Google Scholar

Copyright © 2013 Talambedu Usha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.